Clinical Trial Update: CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update investigating cabozantinib in non-small cell lung cancer with MET deregulation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: Fondazione Ricerca Traslazionale | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN